Medindia

X

Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference

Thursday, June 19, 2008 General News J E 4
Advertisement
SAN DIEGO, June 18 Halozyme Therapeutics, Inc.(Nasdaq: HALO), a biopharmaceutical company developing and commercializingproducts targeting the extracellular matrix, today announced that it willpresent at the Jefferies 2nd Annual Healthcare Conference to be held in NewYork on June 24-26, 2008.

Jonathan Lim, MD, Halozyme's President and Chief Executive Officer, willpresent on Wednesday, June 25, 2008 at 1:00 p.m. Eastern Time (10:00 a.m.Pacific Time) and will discuss the Company's strategic initiatives, productpipeline and market opportunities.

Interested parties can access a live audio webcast and accompanying slidepresentation via the Internet by visiting the Investor Relations section ofthe Company's Web site at http://www.halozyme.com. An archived presentationwill be available on the Web site for 30 days.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializingproducts targeting the extracellular matrix for the drug delivery, metabolism,oncology and dermatology markets. The company's portfolio of products andproduct candidates is based on intellectual property covering the family ofhuman enzymes known as hyaluronidases. The company's Enhanze(TM) Technologyis a novel drug delivery platform designed to increase the absorption anddispersion of biologics. Its key partnerships are with Roche to apply EnhanzeTechnology to Roche's biological therapeutic compounds for up to 13 targetsand with Baxter to apply Enhanze Technology to Baxter's biological therapeuticcompound, GAMMAGARD LIQUID 10%. In addition, the company has received FDAapproval for two products: Cumulase(R), for use in in-vitro fertilization, andHYLENEX, for use as an adjuvant to increase the absorption and dispersion ofother injected drugs and fluids. HYLENEX is partnered with BaxterInternational Inc. The Company also has a number of different enzymes in itsportfolio that are targeting significant areas of unmet need.Halozyme Contact Robert H. Uhl Senior Director, Investor Relations (858) 704-8264 ruhl@halozyme.com

SOURCE Halozyme Therapeutics, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
ARUP Laboratories Partners With Pathology Service ...
S
China Sky One Medical, Inc. Obtains SFDA Approval ...